AI assistant
Novartis AG — Director's Dealing 2019
Apr 5, 2019
940_dirs_2019-04-05_98bdd8ed-16b1-4b6a-b4a0-e5baf3279381.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aerpio Pharmaceuticals, Inc. (ARPO)
CIK: 0001422142
Period of Report: 2019-04-03
Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-04-03 | Common Stock | S | 58033 | $.96 | Disposed | 5193108 | Indirect |
| 2019-04-04 | Common Stock | S | 47900 | $1.01 | Disposed | 5145208 | Indirect |
| 2019-04-05 | Common Stock | S | 24661 | $1.02 | Disposed | 5120547 | Indirect |
Footnotes
F1: Reflects sales of common stock executed in multiple transactions at prices ranging from $0.93 to $1.01. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: Reflects sales of common stock executed in multiple transactions at prices ranging from $0.98 to $1.02. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $0.99 to $1.05. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.